Skip to main content
SpringerLink
Log in

LY 303366

ECB

  • Section 2: Antifungal Agent
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ponsler GD, McMillian CL. Tissue pharmacokinetics of LY303366 and radioactivity in male F344 rats following a single intravenous bolus dose of 5 mg/kg. Pharm Res 1997 Nov; 14 Suppl.: 71

    Google Scholar 

  2. Lucas R, Desante K, Hatcher B, et al. LY303366 single dose pharmacokinetics and safety in healthy male volunteers. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, 108

    Google Scholar 

  3. Rajman I, Desante K, Hatcher B, et al. LY303366 single intravenous dose pharmacokinetics and safety in healthy volunteers. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 158

    Google Scholar 

  4. Ni L, Smith B, Hatcher B, et al. Pharmacokinetics of LY303366 in healthy and HIV-infected volunteers after single-dose oral administration. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego, 489

    Google Scholar 

  5. Zeckner D, Butler T, Boylan C, et al. LY303366, activity in a rat mucocutaneous vaginal candidiasis model. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4–7; Orlando, 252

    Google Scholar 

  6. Zeckner D, Butler T, Boylan C, et al. LY303366, activity in a murine systemic candidiasis model. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 17–20; New Orleans, 186

    Google Scholar 

  7. Zeckner D, Butler T, Boylan C, et al. LY303366, activity against systemic aspergillosis and histoplasmosis in murine models. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 17–20; New Orleans, 186

    Google Scholar 

  8. Verweij PE, Oakley KL, Morrissey J, et al. Efficacy of LY303366 against amphotericin B susceptible and resistant A. fumigatus infection in an immunocompromised murine model. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 158

    Google Scholar 

  9. Current WL, Boylan CJ, Raab PP. Anti-pneumocystis activity of LY303366 and other echinocandin B analogs. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 17–20; New Orleans, 186

    Google Scholar 

  10. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998 Oct; 36: 2950–6

    PubMed  CAS  Google Scholar 

  11. Pfaller MA, Marco F, Messer SA, et al. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L- 743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998 Apr; 30: 251–5

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

LY 303366. Drugs R&D 1, 176–178 (1999). https://doi.org/10.2165/00126839-199901020-00016

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199901020-00016

Keywords

Search

Navigation